New Delhi: Drug firm Sun Pharma on Wednesday said it has received the US health regulator’s approval for the launch of its generic Sumatriptan Succinate injections, used in the treatment of migraines and headaches, in the American market.
The Mumbai-headquartered firm’s US subsidiary has received approval from the US Food and Drug Administration (USFDA) to market Sumatriptan Succinate injections in strength of 6 mg (base)/0.5ml, Sun Pharmaceutical Industries said in a statement.
“Annual sale for Sumatriptan Succinate injections in the US is approximately $190 million,” the company said.
Generic Sumatriptan Succinate injections are equivalent to GlaxoSmithKline’s Imitrex Stat dose system in the same strength, it added.
“Sumatriptan Succinate injection is indicated for the acute treatment of migraine attacks with or without aura and the acute treatment of cluster headache episodes,” it said.
Shares of Sun Pharma were being quoted at Rs 497 apiece in late afternoon trade on the Bombay Stock Exchange (BSE) on Wednesday, up 1.76% from their previous close.